\BOOKMARK [0][-]{section*.4}{List of Figures}{}% 1
\BOOKMARK [0][-]{section*.6}{List of Tables}{}% 2
\BOOKMARK [0][-]{section*.9}{List of Abbreviations}{}% 3
\BOOKMARK [0][-]{section*.11}{Glossary}{}% 4
\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 5
\BOOKMARK [1][-]{section.1.1}{Overview}{chapter.1}% 6
\BOOKMARK [1][-]{section.1.2}{tRNA and disease}{chapter.1}% 7
\BOOKMARK [1][-]{section.1.3}{tRNA biogenesis}{chapter.1}% 8
\BOOKMARK [1][-]{section.1.4}{tRNA sequencing}{chapter.1}% 9
\BOOKMARK [1][-]{section.1.5}{Previous efforts for genome-wide tRNA annotation}{chapter.1}% 10
\BOOKMARK [1][-]{section.1.6}{Small RNA sequencing protocol}{chapter.1}% 11
\BOOKMARK [0][-]{chapter.2}{Hydro-tRNAseq}{}% 12
\BOOKMARK [1][-]{section.2.1}{Experimental innovation}{chapter.2}% 13
\BOOKMARK [1][-]{section.2.2}{Bioinformatics analysis pipeline}{chapter.2}% 14
\BOOKMARK [2][-]{subsection.2.2.1}{Hierarchical sequence read mapping}{section.2.2}% 15
\BOOKMARK [2][-]{subsection.2.2.2}{tRNA gene annotation}{section.2.2}% 16
\BOOKMARK [1][-]{section.2.3}{Pipeline outputs}{chapter.2}% 17
\BOOKMARK [2][-]{subsection.2.3.1}{Mature tRNA alignment}{section.2.3}% 18
\BOOKMARK [2][-]{subsection.2.3.2}{Pre-tRNA alignment}{section.2.3}% 19
\BOOKMARK [1][-]{section.2.4}{Need for pre-tRNA enrichment}{chapter.2}% 20
\BOOKMARK [1][-]{section.2.5}{PAR-CLIP methodology for the study or RNA-RBP interactions}{chapter.2}% 21
\BOOKMARK [1][-]{section.2.6}{SSB PAR-CLIP}{chapter.2}% 22
\BOOKMARK [1][-]{section.2.7}{tRNA gene annotation}{chapter.2}% 23
\BOOKMARK [0][-]{chapter.3}{Applications and biological insights}{}% 24
\BOOKMARK [1][-]{section.3.1}{tRNA gene abundance does not correlate with tRNA gene count on the isotype level}{chapter.3}% 25
\BOOKMARK [1][-]{section.3.2}{tRNA gene abundance does not correlate with tRNA gene count on the isoacceptor level}{chapter.3}% 26
\BOOKMARK [1][-]{section.3.3}{Mature tRNA abundance does not correlate with pre-tRNA abundance}{chapter.3}% 27
\BOOKMARK [1][-]{section.3.4}{tRNA transcription initiation and termination}{chapter.3}% 28
\BOOKMARK [1][-]{section.3.5}{Ribonucleotide modifications}{chapter.3}% 29
\BOOKMARK [1][-]{section.3.6}{Annotation of intron-containing tRNA genes}{chapter.3}% 30
\BOOKMARK [1][-]{section.3.7}{Hydro-tRNAseq application in human disease}{chapter.3}% 31
\BOOKMARK [2][-]{subsection.3.7.1}{Plausible pathomechanisms of CLP1 mutations}{section.3.7}% 32
\BOOKMARK [1][-]{section.3.8}{Comparison with other methods}{chapter.3}% 33
\BOOKMARK [1][-]{section.3.9}{Discussion}{chapter.3}% 34
\BOOKMARK [1][-]{section.3.10}{Summary}{chapter.3}% 35
\BOOKMARK [0][-]{chapter.4}{Materials and methods}{}% 36
\BOOKMARK [1][-]{section.4.1}{Hydro-tRNAseq}{chapter.4}% 37
\BOOKMARK [1][-]{section.4.2}{SSB PAR-CLIP}{chapter.4}% 38
\BOOKMARK [1][-]{section.4.3}{Bioinformatic analysis}{chapter.4}% 39
\BOOKMARK [1][-]{section.4.4}{Accession codes}{chapter.4}% 40
\BOOKMARK [1][-]{section.4.5}{Code availability}{chapter.4}% 41
\BOOKMARK [0][-]{chapter.5}{C3PO}{}% 42
\BOOKMARK [1][-]{section.5.1}{Introduction}{chapter.5}% 43
\BOOKMARK [1][-]{section.5.2}{From manny}{chapter.5}% 44
\BOOKMARK [1][-]{section.5.3}{TSN binds tRNAs}{chapter.5}% 45
\BOOKMARK [1][-]{section.5.4}{C3PO possesses a length- and structure-dependent endonucleolytic activity}{chapter.5}% 46
\BOOKMARK [1][-]{section.5.5}{Biochemical characterization of C3PO\220s tRNA processing activity}{chapter.5}% 47
\BOOKMARK [1][-]{section.5.6}{Functional validation of C3PO\220s targets}{chapter.5}% 48
\BOOKMARK [1][-]{section.5.7}{C3PO sumary report 2014}{chapter.5}% 49
\BOOKMARK [1][-]{section.5.8}{C3PO summary from annual report 2015}{chapter.5}% 50
\BOOKMARK [1][-]{section.5.9}{C3PO summary from annual report 2016}{chapter.5}% 51
\BOOKMARK [0][-]{chapter.6}{Things that didn't work}{}% 52
\BOOKMARK [0][-]{chapter*.49}{References}{}% 53
